论文部分内容阅读
Background:With the improved overall survival(OS) of nasopharyngeal carcinoma(NPC) patients,the importance of quality of life(Qo L) is increasingly being recognized.For some radiosensitive NPC patients,whether low?dose radio?therapy can improve the Qo L without affecting clinical efficacy is unknown.This study aimed to assess the survival rates and Qo L of NPC patients treated with 50 Gy radiotherapy plus hematoporphyrin derivative(HPD).Methods:Forty?six newly diagnosed NPC patients treated with 50 Gy radiotherapy plus HPD between June 1988 and July 1992 were analyzed.All patients were restaged according to the 7th edition of the American Joint Commit?tee on Cancer staging system.The radiotherapy plan was designed on the basis of pretreatment computed tomog?raphy.The OS,local recurrence?free survival(LRFS),distant metastasis?free survival(DMFS),and disease?free survival(DFS) rates were estimated using the Kaplan–Meier method.Qo L was assessed using the Late Radiation Morbidity Scoring Criteria of the Radiation Therapy Oncology Group.Results:The 5?year OS,LRFS,DMFS,and DFS rates were 74.3%,72.6%,82.1%,and 61.2%,respectively.The corre?sponding 10?year rates were 38.4%,62.9%,78.5%,and 49.8%,respectively,and the 20?year rates were 27.7%,51.4%,78.5%,and 40.7%,respectively.None of the patients developed severe radiation?related complications,such as radiation?induced temporal lobe necrosis,hearing loss,trismus,and dysphagia.Conclusion:Some NPC patients were sensitive to 50 Gy radiotherapy plus HPD,and this sensitivity was characterized by long?term survival without significant late treatment morbidities.
Background: With the improved overall survival (OS) of nasopharyngeal carcinoma (NPC) patients, the importance of quality of life (Qo L) is is being being recognized. For some radiosensitive NPC patients, whether low? Dose radio? Therapy can improve the Qo L without affecting clinical efficacy is unknown. This study aimed to assess the survival rates and Qo L of NPC patients treated with 50 Gy radiotherapy plus hematoporphyrin derivative (HPD). Methods: Forty? Six newly diagnosed NPC patients treated with 50 Gy radiotherapy plus HPD Between June 1988 and July 1992 were analyzed. All patients were restaged according to the 7th edition of the American Joint Commit? tee on Cancer staging system. The radiotherapy plan was designed on the basis of pretreatment computed tomog? raphy. The OS, local recurrence Free survival (LRFS), distant metastasis? free survival (DMFS), and disease? free survival (DFS) rates were estimated using the Kaplan-Meier method. Qo L was assessed using the Late Radiation Morbidity Scorin g Criteria of the Radiation Therapy Oncology Group. Results: The 5? year OS, LRFS, DMFS, and DFS rates were 74.3%, 72.6%, 82.1%, and 61.2% respectively. %, 62.9%, 78.5%, and 49.8%, respectively, and the 20-year rates were 27.7%, 51.4%, 78.5%, and 40.7%, respectively. None of the patients developed severe radiation? Related complications, such as radiation ? induced temporal lobe necrosis, hearing loss, trismus, and dysphagia. Confc: Some NPC patients were sensitive to 50 Gy radiotherapy plus HPD, and this sensitivity was characterized by long? term survival without significant late treatment morbidities.